OpGen Inc (NASDAQ:OPGN) has today made the much awaited announcement. It outlined that the New York State Department of Health had approved its new product. This comes as great news to patients around the globe who will reap from the benefits associated with Acuitas® MDRO Gene Test. The various physicians as well as the health providers will be able to offer the much needed medical assistance.
CLIA laboratory has been approved and thus it bears all rights to conduct testing in New York. MDRO gene-testing on the clinical isolates and the perianal swabs is an important step in the medical arena. It goes without saying that indeed the technological advancements sweeping across the globe are helping improve lives in a major way.
OpGen Inc according to Yahoo has always channeled a lot of resources in the area of research over the years. The company’s aim has been to develop some working solutions to help it deal with most of the concerns forwarded by patients worldwide. The recent development has been termed by analysts as a progressive one. There is indeed hope that the company will soon be able to generate higher revenues.
For many years now, NYSDOH has been regulating and overseeing clinical diagnostic laboratories that test the wide array of specimens from the various state residents. The Acuitas MDRO Gene Test according to some reliable sources is a top test with the capacity to deliver information regarding the presence of ten MDRO resistance genes in any given patient.
The Chairman who is also the CEO of the company in a recent meeting said, “We are pleased to receive approval by the NYSDOH to provide our services to healthcare institutions in NY State. The NY State Clinical Lab Evaluation Program conducts rigorous evaluations of new clinical lab tests, and we are honored to receive this important approval for our technology.”
OpGen Inc says that the rising Superbug Multi-drug Resistant pathogen issue is a critical one and promises to do all within its means to combat the problem.
